Indivior Pharmaceuticals, Inc. INDV Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $89M-12.7% | $102M+143% | $42M+133% | $18M-61.7% | $47M+124% | ||
| $2M0.0% | $2M-33.3% | $3M+50.0% | $2M-33.3% | $3M-40.0% | ||
| $9M+80.0% | $5M-28.6% | $7M-12.5% | $8M+33.3% | $6M0.0% | ||
| $27M+171% | -$38M-153% | -$15M-267% | $9M+550% | -$2M-105% | ||
| $6M+100% | $3M-81.3% | $16M— | $0— | $0— | ||
| $20M+433% | -$6M-133% | $18M+550% | -$4M+63.6% | -$11M-375% | ||
| $1M+150% | -$2M— | —— | -$17M-240% | -$5M-350% | ||
| $18M+264% | -$11M-57.1% | -$7M+85.7% | -$49M-372% | $18M— | ||
| -$86M— | —— | —— | $50M-38.3% | $81M— | ||
| $0— | —— | -$1M— | —— | -$1M— | ||
| $2M-33.3% | $3M+50.0% | $2M-33.3% | $3M+50.0% | $2M-50.0% | ||
| -$18M— | —— | —— | —— | $0— | ||
| -$9M+95.9% | -$221M-467% | -$39M-125% | $158M+111% | $75M— | ||
| $20M-16.7% | $24M+20.0% | $20M+17.6% | $17M+240% | $5M-68.8% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $6M+20.0% | $5M+66.7% | $3M-40.0% | $5M-16.7% | $6M-79.3% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $5M-16.7% | $6M+100% | $3M-50.0% | $6M+20.0% | $5M+66.7% | ||
| -$19M+20.8% | -$24M-20.0% | -$20M-17.6% | -$17M-240% | -$5M-163% | ||
| $126M— | —— | —— | —— | $11M-78.0% | ||
| $489M— | —— | —— | —— | $0-100% | ||
| $333M+6,560% | $5M+25.0% | $4M0.0% | $4M0.0% | $4M-98.3% | ||
| $0— | —— | $1M— | —— | $1M— | ||
| $21M+950% | $2M— | —— | —— | $3M+50.0% | ||
| $3M— | —— | —— | $0— | $0— | ||
| $5M— | —— | —— | —— | $0-100% | ||
| $7M+240% | -$5M-66.7% | -$3M+40.0% | -$5M+70.6% | -$17M— | ||
| $0— | $0+100% | -$2M-300% | $1M— | $0-100% | ||
| -$20M+92.1% | -$252M-313% | -$61M-145% | $136M+157% | $53M+71.0% | ||
| $6M+100% | $3M-81.3% | $16M— | $0— | $0— | ||
| $0+100% | -$3M0.0% | -$3M-175% | $4M+300% | $1M-80.0% | ||
| -$38M+87.7% | -$310M— | —— | —— | -$62M-1,140% | ||
| $18M+264% | -$11M-57.1% | -$7M+85.7% | -$49M-372% | $18M— | ||
| $2M-33.3% | $3M+50.0% | $2M-33.3% | $3M+50.0% | $2M-50.0% | ||
| $0— | —— | -$1M— | —— | -$1M— | ||
| —— | $0— | $0— | $0— | $0— | ||
| $5M-16.7% | $6M+100% | $3M-50.0% | $6M+20.0% | $5M+66.7% | ||
| —— | $250K0.0% | $250K0.0% | $250K0.0% | $250K— | ||
| $5M— | —— | —— | —— | $0-100% | ||
| $3M— | —— | —— | $0— | $0— | ||
| $0— | $0+100% | -$2M-300% | $1M— | $0-100% | ||
| -$29M+88.2% | -$245M-315% | -$59M-142% | $141M+101% | $70M— | ||
| -$29M+88.2% | -$245M-315% | -$59M-142% | $141M+101% | $70M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Indivior Pharmaceuticals, Inc. 's cash flow data come from?
- Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.